Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kronos Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
KRON
Nasdaq
8731
https://www.kronosbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kronos Bio Inc
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Apr 24th, 2024 8:01 pm
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?
- Mar 27th, 2024 4:00 pm
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
- Mar 21st, 2024 11:05 am
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
- Mar 7th, 2024 9:05 pm
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
- Mar 5th, 2024 9:44 pm
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
- Feb 27th, 2024 9:05 pm
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
- Jan 25th, 2024 1:00 pm
We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate
- Jan 1st, 2024 10:55 am
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
- Dec 18th, 2023 9:06 pm
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
- Dec 4th, 2023 1:00 pm
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
- Nov 27th, 2023 9:05 pm
Kronos Bio Up 47%, Insider Buyers Are Up 31%
- Nov 20th, 2023 1:18 pm
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
- Nov 13th, 2023 10:25 pm
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
- Nov 13th, 2023 9:05 pm
Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study
- Nov 2nd, 2023 8:05 pm
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
- Nov 2nd, 2023 4:00 pm
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
- Oct 27th, 2023 12:00 pm
Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC
- Oct 13th, 2023 4:30 pm
Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13
- Oct 4th, 2023 8:05 pm
Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development
- Aug 17th, 2023 12:00 pm
Scroll